Johnson & Johnson Nears Approval for $6.5B Long Standing Talc Settlement

Author: Vandana Singh | August 15, 2024 11:03am

Johnson & Johnson (NYSE:JNJ) is expected to confirm a $6.48 billion settlement plan to resolve thousands of lawsuits alleging that its baby powder products cause cancer.

What Happened: Reuters noted that the company will reveal Friday that over 75% of claimants have agreed to the settlement. This surpasses the threshold required for a judge to approve the proposed bankruptcy plan.

A Johnson & Johnson subsidiary will file for bankruptcy protection to finalize the settlement.

Also Read: Medicare Costs For Johnson & Johnson’s Psoriasis Drug Stelara Double When Obtained at Pharmacies.

Support from at least 75% of claimants is a legal prerequisite for advancing the plan to resolve current and future cases.

The voting deadline was July 26. Johnson & Johnson remains confident in achieving the necessary backing.

The company has been sifting through votes from claimants this week. It expects the proposed settlement to proceed to a bankruptcy judge for approval.

Johnson & Johnson’s latest effort represents a renewed attempt to conclude the long-standing talc litigation after courts rejected two prior bankruptcy filings.

In May, Johnson & Johnson announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ovarian cancer arising from cosmetic talc litigation.

The company has already paid approximately $5 billion to settle talc-related claims, including those involving mesothelioma and other cancers and allegations of illegal marketing practices by U.S. states.

Price Action: JNJ stock is up 0.01% at $158.49 at last check Thursday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Read Next:

• In NIH-Cosponsored Monkeypox Virus Study In Congo, SIGA Technologies’ Antiviral Tecovirimat Did Not Improve Lesion Resolution, Stock Tanks.

Posted In: JNJ